Received Jun 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Blotchy rash; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of blotchy rash in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced blotchy rash (Verbatim: Blotchy rash). The outcome of the blotchy rash was not reported. It was unknown if the reporter considered the blotchy rash to be related to Arexvy. It was unknown if the company considered the blotchy rash to be related to Arexvy. Additional Information: GSK receipt date: 03-JUN-2025 The patient reported that glad I received it relief, that I was protected, and had minimum symptoms. Mainly, blotchy rash.